Crossmark

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1186/s40425-018-0442-7

Published Online: 2018-11-23

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Verma, Vivek https://orcid.org/0000-0002-5863-6023
Sprave, Tanja

Haque, Waqar

Simone, Charles B.

Chang, Joe Y.

Welsh, James W.

Thomas, Charles R.
License Information

Text and Data Mining valid from 2018-11-23
More Information

Article History

Received: 12 July 2018

Accepted: 5 November 2018

First Online: 23 November 2018

Ethics approval and consent to participate

: Not applicable secondary to no use of human data.

: Not applicable secondary to no use of human data.

: JWW declares the following conflicts of interest: He is a co-founder of Healios, MolecularMatch, and OncoResponse. He is a scientific board advisor for Reflexion Medical, Checkmate Pharmaceuticals, and Mavu; and he receives clinical research support from BMS and Merck and laboratory research support from Varian, Incyte, Merck, Calithera, Checkmate Pharmaceuticals, and OncoResponse.All other authors have no conflicts of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.